How to buy DexCom (DXCM) stocks

Learn how to easily invest in DexCom stocks.

DexCom is a medical devices business based in the US. DexCom shares (DXCM.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $72.48 – a decrease of 0.82% over the previous day. DexCom employs 9,500 staff and has a trailing 12-month revenue of around $3.9 billion.

How to buy shares in DexCom

  1. Open a brokerage account. Choose from our top broker picks or compare brokers in depth. Then, complete an application.
  2. Fund your account. Add money to your account via bank transfer, debit card or credit card.
  3. Search the platform by ticker symbol. DXCM in this case.
  4. Choose an order type. Place a market order or limit order with your preferred number of shares or dollar amount.
  5. Submit the order. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Best for Beginners

Go to site
Easy to use app
  • 100 free trades signup offer
  • Easy-to-use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Go to site
Low margin rates
  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Low Fees

Go to site
CA & US trading
  • 6% cash rebate plus $2,200 in trading perks
  • Low transaction fees
  • Easy-to-use app

Is it a good time to buy DexCom stock?

Review technicals and fundamentals to help you determine if now's a good time for you to invest.

Technical analysis

View DexCom's price performance, share price volatility, historical data and technicals.

Use our graph to track the performance of DXCM stock over time.

Historical closes compared with the last close of $72.48

1 week (2024-11-12)<svg class="luna-icon luna-icon--success"><use xlink:href="#arrow-up"></use></svg>4.21%
1 month (2024-10-19)<svg class="luna-icon luna-icon--success"><use xlink:href="#arrow-up"></use></svg>5.56%
3 months (2024-08-19)<svg class="luna-icon luna-icon--success"><use xlink:href="#arrow-up"></use></svg>13.25%
6 months (2024-05-19)<svg class="luna-icon luna-icon--error"><use xlink:href="#arrow-down"></use></svg>-41.71%
1 year (2023-11-19)<svg class="luna-icon luna-icon--error"><use xlink:href="#arrow-down"></use></svg>-14.07%
2 years (2022-11-19)<svg class="luna-icon luna-icon--error"><use xlink:href="#arrow-down"></use></svg>-28.20%
3 years (2021-11-19)<svg class="luna-icon luna-icon--error"><use xlink:href="#arrow-down"></use></svg>-48.99%
5 years (2019-11-19)<svg class="luna-icon luna-icon--success"><use xlink:href="#arrow-up"></use></svg>96.70%

The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Is DexCom under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the DexCom P/E ratio, PEG ratio and EBITDA.

DexCom's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, DexCom's stocks trade at around 45x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1173. A PEG ratio close to 1 can be interpreted as meaning shares offer reasonable value for the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $886.8 million ($1 CAD).

The EBITDA is a measure of DexCom's overall financial performance and is widely used to measure a its profitability.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More resources on Finder

More guides on Finder

Go to site